A patient being treated with Bactrim (trimethoprim‑sulfamethoxazole) for cellulitis has developed a rash on her back; what actions should she take?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Discontinue Bactrim Immediately and Contact Your Healthcare Provider

The patient should stop taking Bactrim immediately and contact her healthcare provider as soon as possible, as this rash may represent a serious drug hypersensitivity reaction. 1

Immediate Actions Required

Stop the Medication Now

  • Do not take another dose of Bactrim – the FDA drug label explicitly warns that the medication should be discontinued at the first appearance of skin rash 1
  • A seemingly simple rash can progress to life-threatening conditions including Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) 1

Contact Healthcare Provider Urgently

The patient needs immediate medical evaluation to:

  • Assess the severity and characteristics of the rash
  • Determine if this is a mild drug eruption or early signs of a severe cutaneous adverse reaction (SCAR)
  • Switch to an alternative antibiotic to complete cellulitis treatment

Why This Matters

Bactrim (trimethoprim-sulfamethoxazole) is associated with serious and potentially fatal hypersensitivity reactions, including severe cutaneous adverse reactions that can develop rapidly 1. The FDA label specifically warns about:

  • Stevens-Johnson syndrome and toxic epidermal necrolysis – severe blistering skin reactions with high mortality 1, 2, 3
  • DRESS syndrome – a delayed reaction (typically 2-8 weeks after starting the drug) causing fever, rash, eosinophilia, and multi-organ dysfunction including liver and kidney failure 4, 5, 6
  • Drug-induced leukocytoclastic vasculitis – small vessel inflammation causing palpable purpura 7

Recent case reports document that even after completing a course of Bactrim, patients can develop severe reactions including DRESS with acute liver failure requiring steroid therapy 5 and SJS/TEN overlap requiring prolonged hospitalization 2.

Alternative Antibiotic Options

Once Bactrim is stopped, the healthcare provider should prescribe an alternative antibiotic for cellulitis. For typical nonpurulent cellulitis, appropriate alternatives include 8, 9, 10:

  • Cephalexin (first-generation cephalosporin) – 5-6 days 9, 10
  • Dicloxacillin – 5-6 days 9
  • Amoxicillin – 5-6 days 9
  • Clindamycin – if penicillin-allergic 8

The 2014 IDSA guidelines confirm that for nonpurulent cellulitis (without purulent drainage or abscess), empirical therapy should target β-hemolytic streptococci, and a 5-day course is adequate if clinical improvement occurs 9. The 2021 American College of Physicians best practice advice reinforces that 5-6 days of antibiotics active against streptococci is appropriate 10.

Warning Signs Requiring Emergency Care

Seek emergency medical attention immediately if the patient develops 1:

  • Blistering, peeling, or sloughing of skin
  • Rash involving mucous membranes (mouth, eyes, genitals)
  • Fever with the rash
  • Facial swelling
  • Difficulty breathing, cough, or chest pain
  • Severe fatigue or confusion
  • Yellowing of skin or eyes (jaundice)
  • Decreased urination or dark urine

These symptoms may indicate progression to severe cutaneous adverse reactions or multi-organ involvement requiring hospitalization and systemic corticosteroids 1, 4, 5.

Common Pitfall to Avoid

Do not assume this is a minor "drug rash" that can be ignored while continuing the antibiotic. The FDA label and multiple case reports emphasize that what begins as a simple rash can rapidly evolve into life-threatening conditions 1, 2, 3. The mortality rate for TEN can exceed 30% even with aggressive treatment 3. Early drug discontinuation is the single most important intervention to prevent progression.

Documentation for Future Care

The patient should inform all future healthcare providers about this reaction to Bactrim/sulfa drugs, as:

  • Cross-reactivity exists among sulfonamide-containing medications
  • This reaction should be documented as a drug allergy in the medical record
  • Family members may have pharmacogenetic susceptibility to similar reactions 5

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.